Acorda Therapeutics Inc (NASDAQ:ACOR) Major Shareholder Scopia Capital Management Lp Sells 100,000 Shares of Stock

Acorda Therapeutics Inc (NASDAQ:ACOR) major shareholder Scopia Capital Management Lp sold 100,000 shares of the company’s stock in a transaction dated Thursday, January 17th. The stock was sold at an average price of $16.86, for a total transaction of $1,686,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Scopia Capital Management Lp also recently made the following trade(s):

  • On Wednesday, January 30th, Scopia Capital Management Lp sold 7,000 shares of Acorda Therapeutics stock. The stock was sold at an average price of $16.01, for a total value of $112,070.00.
  • On Friday, January 25th, Scopia Capital Management Lp sold 11,001 shares of Acorda Therapeutics stock. The shares were sold at an average price of $16.02, for a total value of $176,236.02.
  • On Wednesday, January 23rd, Scopia Capital Management Lp sold 97,843 shares of Acorda Therapeutics stock. The stock was sold at an average price of $16.01, for a total transaction of $1,566,466.43.
  • On Tuesday, January 15th, Scopia Capital Management Lp sold 1,700 shares of Acorda Therapeutics stock. The stock was sold at an average price of $16.60, for a total transaction of $28,220.00.
  • On Thursday, January 10th, Scopia Capital Management Lp sold 162,491 shares of Acorda Therapeutics stock. The shares were sold at an average price of $17.18, for a total transaction of $2,791,595.38.
  • On Monday, January 7th, Scopia Capital Management Lp sold 75,000 shares of Acorda Therapeutics stock. The stock was sold at an average price of $16.56, for a total value of $1,242,000.00.
  • On Thursday, January 3rd, Scopia Capital Management Lp sold 23,616 shares of Acorda Therapeutics stock. The stock was sold at an average price of $15.74, for a total transaction of $371,715.84.
  • On Friday, December 28th, Scopia Capital Management Lp sold 52,891 shares of Acorda Therapeutics stock. The shares were sold at an average price of $14.99, for a total transaction of $792,836.09.
  • On Friday, December 28th, Scopia Capital Management Lp sold 52,891 shares of Acorda Therapeutics stock. The stock was sold at an average price of $14.99, for a total transaction of $792,836.09.
  • On Wednesday, December 26th, Scopia Capital Management Lp sold 50,000 shares of Acorda Therapeutics stock. The stock was sold at an average price of $14.66, for a total transaction of $733,000.00.

Shares of Acorda Therapeutics stock opened at $15.42 on Thursday. Acorda Therapeutics Inc has a 52-week low of $12.86 and a 52-week high of $36.35. The stock has a market capitalization of $721.01 million, a PE ratio of 14.83 and a beta of 1.66. The company has a debt-to-equity ratio of 0.57, a current ratio of 4.03 and a quick ratio of 3.95.

A number of hedge funds have recently modified their holdings of the business. Bank of Montreal Can grew its position in Acorda Therapeutics by 100.8% during the 4th quarter. Bank of Montreal Can now owns 2,116 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 1,062 shares during the period. Oppenheimer Asset Management Inc. acquired a new position in shares of Acorda Therapeutics during the fourth quarter worth about $44,000. NumerixS Investment Technologies Inc purchased a new stake in shares of Acorda Therapeutics in the fourth quarter valued at about $77,000. Pacer Advisors Inc. purchased a new position in shares of Acorda Therapeutics during the third quarter valued at approximately $110,000. Finally, Schroder Investment Management Group acquired a new stake in shares of Acorda Therapeutics in the third quarter worth $112,000.

Several analysts have weighed in on the company. BidaskClub downgraded Acorda Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday. ValuEngine raised shares of Acorda Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 1st. HC Wainwright set a $33.00 price target on shares of Acorda Therapeutics and gave the company a “buy” rating in a research report on Wednesday, January 23rd. Oppenheimer set a $18.00 price target on Acorda Therapeutics and gave the stock a “hold acor” rating in a research report on Monday, December 24th. Finally, Cantor Fitzgerald set a $32.00 target price on Acorda Therapeutics and gave the company a “hold” rating in a report on Wednesday, October 31st. Four research analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $25.20.

COPYRIGHT VIOLATION WARNING: “Acorda Therapeutics Inc (NASDAQ:ACOR) Major Shareholder Scopia Capital Management Lp Sells 100,000 Shares of Stock” was first posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.baseballdailydigest.com/news/2019/02/14/scopia-capital-management-lp-sells-100000-shares-of-acorda-therapeutics-inc-acor-stock.html.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.

Featured Story: Why is a lock-up period needed for an IPO?

Insider Buying and Selling by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply